Repatha (Evolocumab) for Teen Girls Ages 12 to 17: School and Activity Guide

What Is Repatha and Why Is a Teen Girl Being Prescribed It?

Repatha (evolocumab) is a monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors in the liver. By preserving those receptors, it removes more LDL-cholesterol from the bloodstream. For teen girls with heterozygous familial hypercholesterolemia (HeFH), LDL levels can run dangerously high despite diet changes and statin therapy.

HeFH affects approximately 1 in 250 people and is inherited in an autosomal dominant pattern, meaning a girl has a 50 percent chance of inheriting it from an affected parent. Without treatment, cumulative LDL exposure from childhood onward accelerates atherosclerosis decades before symptoms appear.

The FDA approved evolocumab for pediatric HeFH in 2021, based on data from the HAUSER-RCT trial. In that randomized, placebo-controlled study of adolescents aged 10 to 17, evolocumab 420 mg monthly reduced LDL-C by a mean of 38.3 percent versus placebo over 24 weeks, with a safety profile consistent with the adult data.

Why Girls and Boys May Have Different Starting Points

Puberty changes LDL metabolism. Estrogen generally lowers LDL and raises HDL, which is one reason premenopausal women have lower cardiovascular event rates than age-matched men. In girls with HeFH, however, this partial estrogen-mediated protection does not fully overcome the genetic LDL burden. Oral contraceptive pills containing estrogen and progestin can modestly raise LDL in some users, which is worth flagging to your prescriber if your teen is also on hormonal contraception.

Trial data in adolescent girls specifically are limited. The HAUSER-RCT enrolled both sexes but did not publish sex-stratified LDL-reduction numbers. This is an acknowledged evidence gap. Dosing and efficacy in adolescent girls are currently extrapolated from combined-sex pediatric data and adult female subgroup analyses, not from a girls-only trial. The trial's published results note no sex-based difference in adverse event rates, but the statistical power for subgroup analysis was low.

Repatha at School: Practical Logistics for Teen Girls

Most teen girls taking Repatha will not need to do anything at school on a typical day. The injection happens at home, either every two weeks (140 mg) or once a month (420 mg). School life is not disrupted by daily dosing because there is no daily dosing.

Three practical issues come up regularly.

Storage: The Autoinjector Cannot Live in a Locker

Evolocumab must be refrigerated at 36 to 46°F (2 to 8°C). According to the FDA prescribing information, the SureClick autoinjector may also be kept at room temperature (up to 77°F / 25°C) for a single period of up to 30 days, after which it must be discarded if unused.

If your injection day falls on a school day and you bring the autoinjector to school to use at home immediately after, keep it in an insulated lunch bag away from direct sunlight. Never store it in a gym locker or a hot car. If your school has a health clinic with a refrigerator, ask the nurse whether your autoinjector can be stored there temporarily on injection day.

Telling the School Nurse: What to Share

You are not required to disclose a medical condition to your school, but giving the school nurse basic information protects you. A brief medication action plan can include:

• Drug name and dosing schedule (so the nurse knows it is not a daily medication)
• Emergency contact for your cardiologist or prescribing clinician
• Confirmation that evolocumab does not cause hypoglycemia, seizures, or acute reactions requiring school intervention
• Storage location and instructions if the device will ever be on school property

Injection-site reactions, the most common side effect reported in the HAUSER-RCT (occurring in roughly 5 to 7 percent of participants), are mild local redness or bruising and resolve within days. They do not require any school-day management.

Scheduling Injections Around Exams and Field Trips

Because evolocumab is a biologic with a half-life of approximately 11 to 17 days in adults, missing a single dose by a few days has minimal pharmacokinetic consequence. You do not need to inject on the exact calendar date if exam week or a school trip creates a conflict. General guidance is to administer the missed dose as soon as possible, then resume the original schedule. Confirm the specific window with your prescriber before shifting dates.

Sports, Gym Class, and Physical Activity

Evolocumab does not limit physical activity. There are no warnings in the FDA label or HAUSER-RCT data about exercise restriction. In fact, aerobic exercise is a complementary strategy for cardiovascular risk reduction, and your care team will likely encourage it.

Injection-Site Rotation for Athletes

If you play a sport that heavily uses your arms (swimming, rowing, volleyball, tennis), the upper arm may not be your best default injection site on the day before or the day of competition. The abdomen and thigh are effective alternatives. FDA prescribing information lists the abdomen, thigh, and upper arm as approved injection sites. Rotating among all three sites reduces cumulative local tissue reaction.

Does Intense Exercise Change How the Drug Works?

There is no published evidence in adolescents or adults showing that vigorous exercise meaningfully alters evolocumab pharmacokinetics. Subcutaneous biologics are absorbed through the lymphatic system and interstitial fluid, not directly through muscle tissue, so working out shortly after an injection is unlikely to accelerate or reduce absorption in a clinically significant way. This specific question has not been studied in teen athletes, and that is an evidence gap worth acknowledging.

Contact Sports and Bruising

Injection-site bruising is a known minor side effect. If you play contact sports (rugby, basketball, soccer), injecting into the abdomen rather than the arms or thighs the day before a game may reduce the chance of a collision worsening bruise formation. This is practical advice, not a medical restriction.

Pregnancy, Contraception, and Reproductive Health: A Required Conversation

Repatha is contraindicated in pregnancy. This section is not optional to read.

Evolocumab is a fully human monoclonal antibody. IgG antibodies cross the placenta, particularly in the second and third trimester, and the fetal consequences of PCSK9 inhibition during development are not established in humans. Animal studies show no direct teratogenicity at doses up to 12 times the human clinical dose, but animal reproductive toxicology does not fully predict human outcomes, and PCSK9 plays a role in lipid metabolism during fetal development.

What the FDA Label Actually Says

The FDA label states: "Based on the mechanism of action of PCSK9 inhibitors and animal data showing PCSK9 inhibitors reduce LDL cholesterol in the developing fetus, Repatha may cause fetal harm." Clinicians are instructed to advise patients of reproductive potential to use effective contraception during treatment.

This matters for teen girls because adolescence is the life stage when sexual debut commonly occurs. A 14-year-old prescribed evolocumab for HeFH who becomes sexually active without contraception carries a real pregnancy risk. The conversation about contraception should happen at the time of prescribing, and it should be revisited at every follow-up.

Lactation

It is not known whether evolocumab is present in human breast milk. IgG antibodies are transferred into breast milk in small quantities, and oral bioavailability of large proteins like monoclonal antibodies is negligible in infants, suggesting systemic exposure to a nursing infant would be very low. The FDA label notes the absence of data and states that the developmental and health benefits of breastfeeding should be considered alongside the mother's need for the drug. For a 12 to 17-year-old, postpartum lactation is a less common scenario, but it is worth noting that no absolute contraindication exists for lactation based on current data. Discuss with your prescriber.

Hormonal Contraception and LDL

Some combined oral contraceptives can modestly increase LDL-C by 5 to 15 percent. If a teen girl on evolocumab is also started on a combined OCP, her LDL may not fall as much as expected. A lipid panel four to eight weeks after starting or changing hormonal contraception is reasonable. Progestin-only methods (the mini-pill, the hormonal IUD, the implant) generally have a smaller LDL effect. This is an active clinical judgment call that your prescribing clinician should address individually.

Life-Stage Considerations Across Adolescence

Early Adolescence (12 to 14): Puberty and LDL Fluctuation

LDL levels shift during puberty. In girls, the increase in estradiol during Tanner stages III through V is associated with a modest protective LDL effect. Despite this, girls with HeFH typically still have LDL levels well above the 130 mg/dL threshold where additional therapy is considered. Starting evolocumab during early puberty is appropriate when statin therapy plus diet changes are insufficient, as defined by ACOG and the American Academy of Pediatrics joint guidance on adolescent cardiovascular risk.

Mid-Adolescence (14 to 16): Academic Pressure and Adherence

The mid-teen years bring academic pressure, irregular schedules, and social self-consciousness about medical devices. An autoinjector pen is noticeable. If a teen is reluctant to inject at home because of fear of needles or embarrassment, address this directly. Needle anxiety affects approximately 25 percent of adolescents and is the most commonly cited barrier to self-injection in this age group. Behavioral strategies (ice for skin numbing, distraction, involving a trusted adult) and clinical support (a nurse-led injection-technique session) reduce this barrier.

The once-monthly 420 mg dose uses three consecutive autoinjector pens administered within 30 minutes at a single session. This can feel overwhelming for a first-time injector. Many teens prefer to start with the every-two-weeks 140 mg single-injection regimen and switch to monthly dosing once they are comfortable. Ask your prescriber if that flexibility is available.

Late Adolescence (16 to 18): Transition to Adult Care

Around age 17 to 18, teens with HeFH begin transitioning to adult cardiology or internal medicine. This is a high-risk period for treatment gaps. Continuity of the Repatha prescription across the insurance transition, the change of providers, and the change of pharmacy relationships requires explicit planning. Before the transition, confirm that the adult-care prescriber is familiar with evolocumab and has access to prior authorization documentation, because PCSK9 inhibitors require payer-specific authorization steps that can delay refills by weeks if not prepared in advance.

A Practical School-Year Injection Planning Framework for Teen Girls on Repatha

Most published resources for adolescents on PCSK9 inhibitors focus on lipid targets and do not address the month-by-month logistics of managing a biologic during a school year. The following planning framework integrates the clinical data with the realities of teen life.

Step 1: Map your injection dates onto the school calendar at the start of each term. Mark every injection date (every 14 days or every 30 days) on a shared calendar with a parent or guardian. Identify conflicts with exam weeks, overnight trips, and sports tournaments four to six weeks in advance.

Step 2: Decide on your injection window. Because evolocumab's half-life is approximately 11 to 17 days, you have a window of plus or minus three to four days around your scheduled date before the pharmacokinetic impact becomes meaningful. Confirm your specific window with your prescriber, since individual variation exists.

Step 3: Assign a backup adult for injection-day accountability. Missed doses in adolescents are most commonly unintentional. Assign one adult (parent, guardian, or school nurse with parental consent) who receives a calendar reminder on injection day. This redundancy costs nothing and prevents the most common adherence failure in this age group.

Step 4: Handle summer differently. Summer disrupts the school-year routine. Heat (above 77°F) degrades the autoinjector if it is stored outside refrigeration for more than 30 days. Travel to warm climates requires a medication cooler. Establish a summer storage plan before the school year ends.

Step 5: Recheck lipids every six to twelve months, not just once. The HAUSER-RCT protocol used lipid panels at baseline, week 12, and week 24. In real-world care, annual or biannual monitoring is standard once stable. If your teen starts or changes hormonal contraception, add an interim lipid panel.

Who This Treatment Is Right for and Who Should Pause

Evolocumab in adolescent girls is appropriate when all of the following are true:

• Confirmed diagnosis of HeFH (genetic testing or clinical criteria using the Simon Broome or Dutch Lipid Clinic criteria)
• Age 12 or older
• LDL-C remaining above goal (typically <130 mg/dL for HeFH, or lower in the presence of other risk factors) despite maximally tolerated statin therapy and dietary changes
• Not currently pregnant; reliable contraception in place if sexually active
• No prior serious hypersensitivity reaction to evolocumab or any excipient in the formulation

Situations where evolocumab should be paused or reconsidered include:

• Confirmed pregnancy (discontinue and discuss alternative lipid management with obstetric care team)
• Serious active infection requiring systemic antibiotics (not a hard contraindication, but discuss timing with prescriber)
• Insurance lapse creating a supply gap (plan ahead; manufacturer patient-assistance programs exist through Amgen's REPATHA SUPPORT program)

Girls with PCOS deserve a specific note here. PCOS is associated with dyslipidemia, insulin resistance, and elevated cardiovascular risk. A teen girl with both PCOS and HeFH carries compounded risk. There is no trial-level evidence specifically examining evolocumab in adolescents with PCOS, so management is individualized. ACOG Practice Bulletin on PCOS recommends lipid monitoring in this population, which is a natural entry point for identifying teens who may benefit from aggressive LDL lowering.

Side Effects That Teen Girls Most Commonly Ask About

The HAUSER-RCT reported the following adverse events at rates above placebo:

• Injection-site reactions: 5 to 7 percent, mild and local
• Nasopharyngitis (common cold): seen in both drug and placebo arms, not clearly drug-related
• Headache: reported in a small percentage, not statistically significant versus placebo
• Back pain: also reported, consistent with adult data

No significant impact on growth, pubertal progression, or menstrual cycle regularity was identified in the 24-week trial period. The HAUSER-OLE open-label extension followed adolescents for an additional 24 weeks (48 weeks total) and found no new safety signals, with sustained LDL reduction.

Cognitive side effects, which were raised as a concern for PCSK9 inhibitors in early adult data, were not observed in the HAUSER-RCT. This is relevant for teens and parents worried about school performance. The FDA's 2018 label update for adult Repatha removed the earlier cognitive-effect language after large-scale adult trial data found no meaningful signal.

Talking to Teachers, Coaches, and Peers

You do not owe anyone a medical explanation. Some coaches will ask about an injection site or autoinjector. A simple statement works: "I have a genetic cholesterol condition and take a monthly injection for it. It does not affect my performance or require any special accommodations."

If a teacher or coach asks you to sit out physical activity due to a visible injection-site bruise, the bruise itself is not a medical contraindication to activity. A brief note from your prescribing clinician stating that evolocumab does not restrict physical activity will resolve most school-side concerns quickly.